AU781996B2 - Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions - Google Patents

Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions Download PDF

Info

Publication number
AU781996B2
AU781996B2 AU26023/00A AU2602300A AU781996B2 AU 781996 B2 AU781996 B2 AU 781996B2 AU 26023/00 A AU26023/00 A AU 26023/00A AU 2602300 A AU2602300 A AU 2602300A AU 781996 B2 AU781996 B2 AU 781996B2
Authority
AU
Australia
Prior art keywords
combination
bretylium
pharmaceutical
composition
anion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26023/00A
Other languages
English (en)
Other versions
AU2602300A (en
Inventor
Marvin B. Bacaner
Maurice M. Kreevoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2602300A publication Critical patent/AU2602300A/en
Application granted granted Critical
Publication of AU781996B2 publication Critical patent/AU781996B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU26023/00A 1999-01-08 2000-01-06 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions Ceased AU781996B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11514399P 1999-01-08 1999-01-08
US60/115143 1999-01-08
US11656799P 1999-01-21 1999-01-21
US60/116567 1999-01-21
PCT/US2000/000350 WO2000040232A2 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Publications (2)

Publication Number Publication Date
AU2602300A AU2602300A (en) 2000-07-24
AU781996B2 true AU781996B2 (en) 2005-06-23

Family

ID=26812887

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26023/00A Ceased AU781996B2 (en) 1999-01-08 2000-01-06 Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Country Status (10)

Country Link
US (1) US6482811B1 (enExample)
EP (1) EP1140054B1 (enExample)
JP (1) JP4750278B2 (enExample)
AT (1) ATE290857T1 (enExample)
AU (1) AU781996B2 (enExample)
CA (1) CA2358459C (enExample)
DE (1) DE60018704T2 (enExample)
IL (2) IL144199A0 (enExample)
MX (1) MXPA01007024A (enExample)
WO (1) WO2000040232A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
KR20080017489A (ko) 2005-07-22 2008-02-26 더 프록터 앤드 갬블 캄파니 약물 유발성 부정맥 발생률 감소용 조성물
JP4750499B2 (ja) * 2005-08-01 2011-08-17 日華化学株式会社 イオン性液体並びにそれを用いた抗菌剤及び抗菌性繊維
EP2953627A4 (en) * 2013-02-07 2017-03-29 Research Foundation Of The City University Of New York NSAIDs DERIVATIVES AND USES THEREOF
CA2998875C (en) 2015-09-17 2023-08-29 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
EP4117660B1 (en) * 2020-03-11 2025-11-05 Ohio State Innovation Foundation Methods of modulating t-cell activation and treating chronic heart failure using carboranes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
US3911125A (en) * 1973-05-23 1975-10-07 Marvin B Bacaner Method of treating angina pectoris, coronary insufficiency, and preventing myocardial infarction
US4147768A (en) 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
JPH01500589A (ja) * 1986-03-21 1989-03-01 ユーラシアム　ラボラトリーズ　インコーポレーテツド 薬剤組成物
US5036106A (en) * 1989-09-05 1991-07-30 Bacaner Marvin B Methods for the treatment of disorders of the cardiac vascular system
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JP3355593B2 (ja) 1994-08-19 2002-12-09 信越化学工業株式会社 固形腸溶製剤の製造方法
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
JP3149122B2 (ja) 1994-11-07 2001-03-26 信越化学工業株式会社 固形腸溶製剤のコーティング用基剤
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5980951A (en) 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEUBERT R ET AL. PHARM. IND. 54(4), 1992, 370-2 *
NEUBERT R ET AL. PHARMAZIE, 45 (1990), H.4, 233-7 *

Also Published As

Publication number Publication date
EP1140054B1 (en) 2005-03-16
ATE290857T1 (de) 2005-04-15
CA2358459A1 (en) 2000-07-13
EP1140054A2 (en) 2001-10-10
US6482811B1 (en) 2002-11-19
DE60018704D1 (de) 2005-04-21
DE60018704T2 (de) 2006-05-04
IL144199A (en) 2006-10-05
JP4750278B2 (ja) 2011-08-17
CA2358459C (en) 2011-05-24
WO2000040232A3 (en) 2000-11-23
IL144199A0 (en) 2002-05-23
JP2002534379A (ja) 2002-10-15
AU2602300A (en) 2000-07-24
WO2000040232A2 (en) 2000-07-13
MXPA01007024A (es) 2002-03-27

Similar Documents

Publication Publication Date Title
US6884792B2 (en) Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
AU781996B2 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
PT1789433E (pt) Métodos de tratamento de vermelhidão cutânea usando agonistas selectivos do receptor adrenérgico alfa-2
JP3852621B2 (ja) 血管内皮細胞機能改善剤
US20200054585A1 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
AU2022241499A1 (en) S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
KR20080025034A (ko) Ｑｔ 간격 조절 방법
JPH0142246B2 (enExample)
CN110913851A (zh) 治疗外伤性脑损伤的组合物和方法
US20220259164A1 (en) Use of aminothiol compounds as cerebral nerve or heart protective agent
CN115667234A (zh) 美托哌丙嗪的新型多晶型形式
JP5960695B2 (ja) パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用
JPH10298077A (ja) 心筋症の治療、予防剤
US7074773B2 (en) Pharmaceutical composition for diabetic neuropathy
JP2957618B2 (ja) アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物
KR20250005055A (ko) 아스피린 및 기타 nsaid의 고 침투성 전구약물을 이용한 심혈관 질환의 예방 또는 치료
JPH0848630A (ja) 筋緊張性ジストロフィー症治療剤
CN109730988A (zh) 1，3-丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途
US11858908B2 (en) Compositions and methods for inhibiting IDO1
JPH0480004B2 (enExample)
US12502371B2 (en) Drug for treating and preventing dementia
US20030065015A1 (en) Novel quarternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions
US4218466A (en) Method of treating gastric and duodenal ulcers
WO2019131308A1 (ja) ９‐β‐Ｄ‐アラビノフラノシルヒポキサンチンによる不整脈治療
ZA200105931B (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions.

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20010703